Advertisement
Advertisement
INSM
Insmed, Inc.
161.68
USDSponsored
-3.19
-1.93%
Apr 02, 15:11 UTC -4
Open
INSM Earnings Reports
Positive Surprise Ratio
INSM beat 15 of 41 last estimates.
37%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$306.28M
/-$1.01
Implied change from Q4 25 (Revenue/ EPS)
+16.09%
/-34.42%
Implied change from Q1 25 (Revenue/ EPS)
+229.96%
/-28.87%
Insmed, Inc. earnings per share and revenue
On Jan 09, 2026, INSM reported earnings of -1.54 USD per share (EPS) for Q4 25, missing the estimate of -1.31 USD, resulting in a -16.99% surprise. Revenue reached 263.84 million, compared to an expected 174.83 million, with a 50.91% difference. The market reacted with a +6.54% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -1.01 USD, with revenue projected to reach 306.28 million USD, implying an decrease of -34.42% EPS, and increase of 16.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.08
Surprise
-16.19%
Bicara Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.68
Actual
-$0.68
Surprise
+0.66%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.17
Surprise
+7.41%
Neumora Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.33
Actual
-$0.35
Surprise
-5.39%
Sangamo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-14.38%
RenovoRx, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
INmune Bio Inc. Common stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.18
Surprise
+32.13%
PDS Biotechnology Corporation Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.14
Surprise
+27.76%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-17.65%
Lantern Pharma Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.36
Surprise
+23.27%
FAQ
What were Insmed, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Insmed, Inc. reported EPS of -$1.54, missing estimates by -16.99%, and revenue of $263.84M, 50.91% above expectations.
How did the market react to Insmed, Inc.'s Q4 2025 earnings?
The stock price moved up 6.54%, changed from $151.11 before the earnings release to $161.00 the day after.
When is Insmed, Inc. expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Insmed, Inc.'s next earnings report?
Based on 10
analysts, Insmed, Inc. is expected to report EPS of -$1.01 and revenue of $306.28M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement